During the past decade, Elman Retina Group, P.A. conducted 23 clinical trials. In the 10-year time frame, 23 clinical trials started and 16 clinical trials were completed, i.e. on average, 69.6% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 10 clinical trials were completed. i.e. 125% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Elman Retina Group, P.A." #1 sponsor was "Jaeb Center for Health Research" with 20 trials, followed by "Notal Vision Ltd." with 3 trials sponsored, "Apellis Pharmaceuticals, Inc." with 2 trials sponsored, "Elman Retina Group" with 2 trials sponsored and "Genentech, Inc." with 2 trials sponsored. Other sponsors include 11 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Elman Retina Group, P.A." #1 collaborator was "National Eye Institute (NEI)" with 21 trials as a collaborator, "National Institutes of Health (NIH)" with 7 trials as a collaborator, "Genentech, Inc." with 5 trials as a collaborator, "Allergan" with 4 trials as a collaborator and "Juvenile Diabetes Research Foundation" with 4 trials as a collaborator. Other collaborators include 14 different institutions and companies that were collaborators in the rest 21 trials.

According to Clinical.Site data, the most researched conditions in "Elman Retina Group, P.A." are "Diabetic Macular Edema" (15 trials), "Diabetic Retinopathy" (8 trials), "Geographic Atrophy" (5 trials), "Proliferative Diabetic Retinopathy" (5 trials) and "Age Related Macular Degeneration" (3 trials). Many other conditions were trialed in "Elman Retina Group, P.A." in a lesser frequency.

Most popular intervention types in "Elman Retina Group, P.A." are "Drug" (31 trials), "Procedure" (10 trials), "Other" (7 trials), "Device" (5 trials) and "Behavioral" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Deferred aflibercept" (2 trials), "Deferred laser" (2 trials), "Lampalizumab" (2 trials) and "Prompt aflibercept" (2 trials). Other intervention names were less common.

The vast majority of trials in "Elman Retina Group, P.A." are 45 trials for "All" genders.

Currently, there are NaN active trials in "Elman Retina Group, P.A.". undefined are not yet recruiting, 4 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Elman Retina Group, P.A., undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Elman Retina Group, P.A., 2 "Phase 1" clinical trials were conducted, 16 "Phase 2" clinical trials and 20 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 3 trials that are defined as “Not Applicable".